Literature DB >> 24578407

Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer.

Paul De Leyn1, Christophe Dooms, Jaroslaw Kuzdzal, Didier Lardinois, Bernward Passlick, Ramon Rami-Porta, Akif Turna, Paul Van Schil, Frederico Venuta, David Waller, Walter Weder, Marcin Zielinski.   

Abstract

Accurate preoperative staging and restaging of mediastinal lymph nodes in patients with potentially resectable non-small-cell lung cancer (NSCLC) is of paramount importance. In 2007, the European Society of Thoracic Surgeons (ESTS) published an algorithm on preoperative mediastinal staging integrating imaging, endoscopic and surgical techniques. In 2009, the International Association for the Study of Lung Cancer (IASLC) introduced a new lymph node map. Some changes in this map have an important impact on mediastinal staging. Moreover, more evidence of the different mediastinal staging technique has become available. Therefore, a revision of the ESTS guidelines was needed. In case of computed tomography (CT)-enlarged or positron emission tomography (PET)-positive mediastinal lymph nodes, tissue confirmation is indicated. Endosonography [endobronchial ultrasonography (EBUS)/esophageal ultrasonography (EUS)] with fine-needle aspiration (FNA) is the first choice (when available), since it is minimally invasive and has a high sensitivity to rule in mediastinal nodal disease. If negative, surgical staging with nodal dissection or biopsy is indicated. Video-assisted mediastinoscopy is preferred to mediastinoscopy. The combined use of endoscopic staging and surgical staging results in the highest accuracy. When there are no enlarged lymph nodes on CT and when there is no uptake in lymph nodes on PET or PET-CT, direct surgical resection with systematic nodal dissection is indicated for tumours ≤ 3 cm located in the outer third of the lung. In central tumours or N1 nodes, preoperative mediastinal staging is indicated. The choice between endoscopic staging with EBUS/EUS and FNA or video-assisted mediastinoscopy depends on local expertise to adhere to minimal requirements for staging. For tumours >3 cm, preoperative mediastinal staging is advised, mainly in adenocarcinoma with high standardized uptake value. For restaging, invasive techniques providing histological information are advisable. Both endoscopic techniques and surgical procedures are available, but their negative predictive value is lower compared with the results obtained in baseline staging. An integrated strategy using endoscopic staging techniques to prove mediastinal nodal disease and mediastinoscopy to assess nodal response after induction therapy needs further study.

Entities:  

Keywords:  Endoscopic staging; Lung cancer; Preoperative staging; Restaging; Surgical staging

Mesh:

Year:  2014        PMID: 24578407     DOI: 10.1093/ejcts/ezu028

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  188 in total

1.  Evidence for Expanding Invasive Mediastinal Staging for Peripheral T1 Lung Tumors.

Authors:  Emily A DuComb; Benjamin A Tonelli; Ya Tuo; Bernard F Cole; Vitor Mori; Jason H T Bates; George R Washko; Raúl San José Estépar; C Matthew Kinsey
Journal:  Chest       Date:  2020-06-26       Impact factor: 9.410

2.  Magnetic resonance imaging for staging of non-small-cell lung cancer-technical advances and unmet needs.

Authors:  Gregor Sommer; Bram Stieltjes
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

Review 3.  Ultrasound techniques in the evaluation of the mediastinum, part I: endoscopic ultrasound (EUS), endobronchial ultrasound (EBUS) and transcutaneous mediastinal ultrasound (TMUS), introduction into ultrasound techniques.

Authors:  Christoph Frank Dietrich; Jouke Tabe Annema; Paul Clementsen; Xin Wu Cui; Mathias Maximilian Borst; Christian Jenssen
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

4.  PET-CT limitations in early stage non-small cell lung cancer: to whom more aggressive approach in radiotherapy and surgery should be directed?

Authors:  Lucyna Kepka; Joanna Socha
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

Review 5.  Ultrasound techniques in the evaluation of the mediastinum, part 2: mediastinal lymph node anatomy and diagnostic reach of ultrasound techniques, clinical work up of neoplastic and inflammatory mediastinal lymphadenopathy using ultrasound techniques and how to learn mediastinal endosonography.

Authors:  Christian Jenssen; Jouke Tabe Annema; Paul Clementsen; Xin-Wu Cui; Mathias Maximilian Borst; Christoph Frank Dietrich
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

6.  Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer.

Authors:  M Majem; J Hernández-Hernández; F Hernando-Trancho; N Rodríguez de Dios; A Sotoca; J C Trujillo-Reyes; I Vollmer; R Delgado-Bolton; M Provencio
Journal:  Clin Transl Oncol       Date:  2019-06-06       Impact factor: 3.405

Review 7.  Uses, limitations, and complications of endobronchial ultrasound.

Authors:  Bilal A Jalil; Kazuhiro Yasufuku; Amir Maqbul Khan
Journal:  Proc (Bayl Univ Med Cent)       Date:  2015-07

Review 8.  Is surgery still the best management option for early stage NSCLC?

Authors:  Aurel Ottlakan; Nicola Martucci; Gaetano Rocco
Journal:  Transl Lung Cancer Res       Date:  2014-06

Review 9.  Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis.

Authors:  Erik Folch; Daniel B Costa; Jeffrey Wright; Paul A VanderLaan
Journal:  Transl Lung Cancer Res       Date:  2015-08

10.  Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer.

Authors:  Julian Kirchner; Lino M Sawicki; Felix Nensa; Benedikt M Schaarschmidt; Henning Reis; Marc Ingenwerth; Simon Bogner; Clemens Aigner; Christian Buchbender; Lale Umutlu; Gerald Antoch; Ken Herrmann; Philipp Heusch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-03       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.